ABSTRACT-(+)-3-(3-Hydroxyphenyl)-N-(l-propyl)piperidine ((+)-3-PPP), a sigma ligand, at doses above 3 mg/kg (s.c.) increased the ambulatory activity of rats, while the (-) isomer of 3-PPP with low affinity for sigma receptors, did not significantly modify the ambulatory activity at 10 and 30 mg/kg (s.c.). The ambulation-increasing effect of (+)-3-PPP was prevented by the sigma receptor antagonists BMY 14802 and rimcazole or the sigma/dopamine D2 antagonist haloperidol. The (+)-3-PPP effect was also attenuated by pretreatment with the monoamine depletor reserpine or the tyrosine hydroxylase inhibitor a-methyltyrosine, but was not affected by the tryptophan hydroxylase inhibitor p-chlorophenylalanine. Moreover, the (+)-3-PPP effect was antagonized by the dopamine D2 antagonist sulpiride, whereas pretreat ment with the 5-HT1A agonist 8-OH-DPAT and the a-adrenoceptor antagonist phenoxybenzamine did not exert any significant effect. These results indicate that sigma receptors are involved in the neuronal mechanism(s) of hyperambulation induced by (+)-3-PPP, and the sigma system may exert both a presynap tic action and a dopamine D2 receptor-mediated action to increase the central dopaminergic function.
(+)-3-PPP has agonistic and/or antagonistic activity at postsynaptic dopamine receptors (1, 3, 4) . However, these suggestions were not supported by in vitro findings, in which (+)-3-PPP failed to activate dopamine auto receptors, mediating inhibition of dopamine release from the rat striatal slices (4) ; and it has relatively low binding affinity for dopamine receptors (2, 5 7). Radioreceptor binding assays have shown that (+)-3 PPP exhibits approximately 1000 times greater affinity for sigma receptors than for dopamine D2 receptors in the central nervous system (8) (9) (10) . Therefore, (+)-3-PPP is widely used as a sigma ligand. Behavioral studies have shown that low doses of (+)-3-PPP produce inhibited locomotor activity in mice and rats, but at higher doses, it causes hyperactivity (1, 3, 11) . The neuronal mecha nism(s) of hyperactivity induced by (+)-3-PPP, however, remain unclear. Since pentazocine and (+)-SKF 10,047, other sigma ligands, also stimulate locomotor behavior in rats (12, 13) , the central sigma system may be closely in volved in the mechanism(s) of hyperlocomotion induced by (+)-3-PPP. In this study, we attempted to find a role for the sigma recognition site in the mediation of hyperactivity induced by (+)-3-PPP.
MATERIALS AND METHODS

Animals
Male Wistar rats were purchased at 5 weeks of age from the Shizuoka Laboratory Animal Center (Shizuoka). Five rats per cage (25 x 35 x 20 cm) were housed and maintain ed under controlled conditions of room temperature (23 ± 1 V), relative humidity (55 ± 5 %) and a 12-hr light, 12-hr dark cycle (light on 07:00 hr) with free access to food and water. The experiment was conducted when the rats reached 6 weeks of age and weighed 130 to 170 g. Each experimental and control group consisted of 5-20 animals, and all the animals were used only once in the ex periment. In the oral dosing study, the animals were fast ed overnight. 
Measurement of ambulatory activity
The rat's ambulatory activity was automatically record ed with a tilting-type ambulometer (ACTY-303; Bio Medica, Ltd., Osaka), consisting of a plastic activity cage (30 cm in diameter, 30 cm in height). The ambulatory ac tivities of 10 rats were measured simultaneously using Rats were individually placed in the cages, and the ambulatory activity of each animal was measured. Experiments were performed between 10:00 hr to 17:00 hr.
Drug treatments
In the single administration study, the ambulatory activ ity of each animal was measured at 10-min intervals for 60 min before and after subcutaneous administration of 3-PPP enantiomers. In the coadministration study, a dose of 30 mg/kg of (+)-3-PPP, a sigma ligand, was in jected subcutaneously 30 or 60 min after intraperitoneal or oral administration of central-acting drugs. The am bulatory activity for 30 or 60 min before and for 60 min after the (+)-3-PPP injection was measured. The sigma/dopamine D2 antagonist haloperidol (0.1 and 1 mg/kg), the sigma antagonist BMY 14802 (3, 10 and 30 mg/kg) and the dopamine D2 antagonist sulpiride (10 and 30 mg/kg) were administered orally 60 min prior to the (+)-3-PPP injection. The 5-HTIA agonist 8-OH-DPAT (0.3 and 1 mg/kg), the a-adrenoceptor antagonist phe noxybenzamine (10 mg/kg) and the sigma antagonist rim cazole (3, 10 and 30 mg/kg) were injected intraperitoneal ly 30 min before (+)-3-PPP administration. a-MT (250 mg/kg, i.p.), a tyrosine hydroxylase inhibitor, and reser pine (2 mg/kg, s.c.), a monoamine depletor, were given 4 and 6 hr before the (+)-3-PPP injection, respectively. p CPA (200 mg/kg), a tryptophan hydroxylase inhibitor, was administered intraperitoneally once a day for 3 con secutive days, and (+)-3-PPP was injected 24 hr after the final administration of p-CPA. Controls received equiva lent volumes of the vehicle by the same route.
Statistics
The results are presented as the means±S.E.M. The statistical evaluation was performed by the Kruskal Wallis nonparametric one-way analysis of variance (ANOVA), followed by the Mann-Whitney U-test. Differ ences were considered significant if the probability of error is less than 5 °Io . 
RESULTS
Effects of 3-PPP enantiomers on ambulatory activity As shown in Fig. 1 , (+)-3-PPP had a biphasic effect on ambulatory activities in rats. Namely, (+)-3-PPP, at a subcutaneous dose of 1 mg/kg, decreased the ambulatory activity as compared with the vehicle-treated control group, but at doses of 3, 10 and 30 mg/kg, it increased the ambulation in a dose-dependent fashion, except that the effect at the highest dose used, 60 mg/kg, was less po tent than that at 30 mg/kg. The peak time of the ambula tion-increasing effect of (+)-3-PPP was 40-50 min after the administration (Fig. IA) , and the dose of (+)-3-PPP that induced the maximal response in overall activity for 60 min after administration was 30 mg/kg (Fig. 1B) . On the other hand, subcutaneous doses of 10 and 30 mg/kg of (-)-3-PPP slightly inhibited the ambulatory activities as compared with the control. (Fig. 2, A and B) . 
Effects of various central-acting drugs on (+)-3-PPP induced hyperambulation
The subcutaneous dose of 30 mg/kg of (+)-3-PPP, which produced the maximal behavioral effect, was adopt ed in this experiment. As shown in Fig. 3 , the ambula tion-increasing effect of (+)-3-PPP was markedly inhibit ed by pretreatment with a subcutaneous dose of 2 mg/kg of reserpine or an intraperitoneal dose of 250 mg/kg of a MT. However, the (+)-3-PPP-induced hyperactivity was negligibly modified by p-CPA (3 x 200 mg/kg, i.p.) (Fig.  3C) . Moreover, the effects of (+)-3-PPP were prevented in a dose-dependent manner by pretreatment with oral doses of BMY 14802 (3, 10 and 30 mg/kg), haloperidol (0.1 and 1 mg/kg) and sulpiride (10 and 30 mg/kg), and with intraperitoneal doses of rimcazole (3 and 10 mg/kg) (Figs. 4 and 5B). Especially, a dose of 30 mg/kg of BMY 14802 and 1 mg/kg of haloperidol blocked (+)-3-PPP-in duced hyperactivity almost completely. An increased dose of 30 mg/kg of rimcazole significantly and partially reduced (+)-3-PPP-induced hyperambulation, and its inhibitory activity was similar to that of 10 mg/kg. All doses used of BMY 14802, haloperidol, sulpiride and rim cazole did not exert any effect as compared with the con trol group on 30-min or 1-hr overall counts of ambulatory activity prior to the (+)-3-PPP treatment (data are not shown). On the other hand, 8-OH-DPAT (0.3 and 1 mg/kg, i.p.) tended to potentiate the hyperambulation induced by (+)-3-PPP (Fig. 5A ). Phenoxybenzamine (10 mg/kg, i.p.) had no effect on the (+)-3-PPP effect (Fig.  5C ). In addition, these authors have reported that both lower doses of (+)-3-PPP and the (-) isomer of 3-PPP inhibit locomotor activities in mice and rats. The present results with a low dose (1 mg/kg, s.c.) of (+)-3-PPP and subcutaneous doses of 10 and 30 mg/kg of (-)-3-PPP are also in support of them, although to clearly detect the inhibitory effect of drugs on ambulatory activity may be difficult because the present study was performed under habituated conditions.
We demonstrated that the ambulation-increasing effect of (+)-3-PPP is prevented by both BMY 14802 (14, 15) and rimcazole (16, 17) , sigma receptor antagonists with negligible affinity for dopamine D, and D2 receptors, and the sigma/dopamine D2 antagonist haloperidol (15) . The anti-(+)-3-PPP effect of BMY 14802 was much more po tent than that of rimcazole. The finding might be ex plained by the biochemical data (15) that the sigma bind ing affinity of BMY 14802 (IC50=74 nM) is about 20 times greater than that of rimcazole (IC50=1460 nM). BMY 14802 also binds to 5-HT,A receptors and exerts agonistic action (18, 19) . The anti-(+)-3-PPP action of BMY 14802 seems not to be due to its 5-HTIA effects, since 8-OH-DPAT, a selective 5-HTIA agonist, failed to attenuate the (+)-3-PPP-induced hyperambulation. Ac cordingly, these results indicate the involvement of sigma receptors in the neuronal mechanisms of (+)-3-PPP induced hyperactivity.
Sigma receptors are generally enantioselective for (+) isomers (10) . (+)-3-PPP has high affinity for sigma receptors, while the (-)-enantiomer has low affinity (8, 20) . As described above, induction of hyperactivity by 3-PPP was confirmed to be enantioselec tive for the (+) isomer of 3-PPP, as well as for the sigma binding affinities of 3-PPP enantiomers. Recently, sub types of sigma receptors, termed sigma-1 and sigma-2, have been postulated on the basis of ligand binding and biochemical studies (21) . It has been demonstrated that (+)-SKF 10,047 and (+)-pentazocine selectively recog nize sigma-1 sites, and (+)-3-PPP binds to both sigma-1 and -2 sites. Sigma-1 ligands such as pentazocine and (+)-SKF 10,047 stimulate locomotor behavior in rodents (12, 13) . Thus, hyperambulation by (+)-3-PPP is likely to be produced through action on the sigma-1 sites.
(+)-3-PPP-induced hyperambulation was inhibited by pretreatment with a monoamine depletor (reserpine), a catecholamine synthesis inhibitor (a-MT) and a selective dopamine D2 antagonist (sulpiride), but was not prevent ed by a serotonin synthesis inhibitor (p-CPA) and an a adrenoceptor antagonist (phenoxybenzamine). These find ings may indicate that the (+)-3-PPP effect results from its presynaptic and dopamine D2 receptor-mediated ac tions on the central dopaminergic system rather than on the noradrenergic and serotonergic systems. The modu lation of dopaminergic neuronal activity by (+)-3-PPP may be mediated through sigma, but not dopamine recep tors because of the relatively poor affinity of (+)-3-PPP for dopamine receptors in vitro (2, 5 7) . This viewpoint is supported by several lines of evidence that sigma recep tors interact closely with the dopaminergic system. Name ly, anatomical studies have shown that sigma receptors are distributed in the substantia nigra, striatum, nucleus accumbens and the other areas where dopamine is plenti ful (20, 22, 23) and that sigma receptors may be located on both dopaminergic neurons in the substantia nigra pars compacta and presynaptic dopaminergic terminals in the striatum (24) . Moreover, electrophysiological studies have shown that sigma ligands modulate the activity of dopaminergic neurons in areas A9 and A10 (17, 25) .
In conclusion, we suggest that sigma receptors are in volved in the neuronal mechanism(s) of hyperambulation induced by high doses of (+)-3-PPP and the sigma sys tem may exert both a presynaptic action and a dopamine D2 receptor-mediated action to increase the central dopa minergic function.
